%0 Generic %A K., Reich %A J.-P., Ortonne %A U., Kerkmann %A Y., Wang %A J.-H., Saurat %A K., Papp %A R., Langley %A C.E.M., Griffiths %D 2017 %T Erratum: Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial %U https://karger.figshare.com/articles/dataset/Erratum_Skin_and_Nail_Responses_after_1_Year_of_Infliximab_Therapy_in_Patients_with_Moderate-to-Severe_Psoriasis_A_Retrospective_Analysis_of_the_EXPRESS_Trial/5241232 %R 10.6084/m9.figshare.5241232.v1 %2 https://karger.figshare.com/ndownloader/files/8955829 %K Nail psoriasis %K Psoriasis %K Nail Psoriasis Severity Index %K Biologic agent %K Infliximab %X Background: The EXPRESS study demonstrated the initial efficacy of infliximab in psoriasis affecting the skin and nails. Objective: To further assess how patients with a positive initial response to infliximab respond to 1 year of continuous infliximab treatment. Methods: A retrospective analysis of patients with moderate-to-severe plaque and nail psoriasis who initiated and continued infliximab treatment up to week 46 was conducted. Results: Among all nail psoriasis patients receiving 1 year of infliximab (n = 186), 74.6 and 54.1% achieved at least 75 or 90% improvement in the Psoriasis Area and Severity Index (PASI) at week 50. These PASI-75 (n = 138) and PASI-90 (n = 100) responders had respective mean improvements from baseline to week 50 of 93.6 and 97.3% for the PASI, 90.6 and 94.1% for the Dermatology Life Quality Index (DLQI) and 78.2 and 80.3% for the Nail Psoriasis Severity Index (NAPSI). Conclusions: Infliximab treatment for 1 year produced sustained improvement in PASI, DLQI and NAPSI scores. %I Karger Publishers